Navigation Links
Major source of radon exposure overlooked at former Ohio uranium-processing plant
Date:10/23/2008

os, known by the code name "Q-11," centrally located near a major production area. The silos were originally used to store high grade uranium ore and later held byproducts from the ore chemical separation process known as raffinate.

"The initial site review conducted by the federal government overlooked the Q-11 silos as a source of radon emissions," says Hornung, a professor of environmental health at UC and director of the biostatistics and data core at Cincinnati Children's Hospital Medical Center. "This second source of radon dominates the total radon exposure from both sources during the period of 1952 to 1958 for workers near the Q-11 silos. Our study revealed that a small number of Fernald workers' cumulative radon exposures were in the range of underground uranium miners."

"When the plant was in operation, employees wore badges to measure gamma radiation exposurebut not alpha radiation sources like radon," he adds.

According to company records, 7,143 people worked at the uranium processing plant between 1952 and the plant's closing in 1989.

Uranium is a heavy metal that is essential for operation of electricity-producing nuclear reactors around the world. The metal can be removed from ore through a chemical separation process that leaves a soupy mixture of liquid and chemical byproducts known as "raffinate." That raffinate was stored in the K-65 silos.

"Uranium raffinate has high levels of radium and radon decay products," explains Pinney, "and for more than 30 years the K-65 silos emitted radon gas into the plant's atmosphere. The gas is odorless and colorless, so the workers never knew they were breathing it."

According to the National Academy of Sciences, radon is the second leading cause of lung cancer in the United States. The substance, which can be dispersed in the form of gas through air or water, genetically alters cells in the lung's lining and can greatly increase a person's risk for lun
'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. deCODE discovers cause of major subtype of glaucoma
2. Bleeding, not inflammation, is major cause of early lung infection death
3. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
4. Leading experts cite poor health and nutrition as major barrier to education in developing world
5. Majority of Americans want local action on global warming, says poll
6. How schizophrenia develops: Major clues discovered
7. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
8. NIH selects LIAI for major study on allergy molecular causes and possible treatments
9. Local sources major cause of US near-ground aerosol pollution
10. Tree of life for flowering plants reveals relationships among major groups
11. Humans not the major target of Shiga toxin
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2